Formulary e-News:
Having trouble viewing this email? View in a browser.
|
You are subscribed to %%list.name%% as %%emailaddr%%. Unsubscribe.

|
to Formulary e-News
|
|
 |
|
 |
Survey
This month we would like to know...
With the recent announcement of Medco's acquisition by Express Scripts, potentially bringing 2 of the nation's largest PBMs together, what do you see as the most significant implications of such consolidation for the industry?
a) Enhanced competition within the industry, inevitably translating to even lower drug costs for PBM payer clients.
b) Unfair advantages for Express Scripts based upon its size, thus reducing competition and potentially increasing long-term costs for payers.
c) Increased pressures on retail pharmacies forcing more pharmacies out of business.
d) Increased quality of PBM clinical, analytic and administrative services across the industry, as other PBMs strive to stay competitive.
e) Minimal, if any, impact.
|
|
|
The Pediatric Infectious Disease Society and the Infectious Disease Society of America have developed the first-ever guidelines on diagnosing and treating community-acquired pneumonia (CAP) in infants and children. The guideline was published online August 30th in Clinical Infectious Disease. Read full article. |
 |
 |
Lixisenatide (Lyxumia, Sanofi), a once-daily GLP-1 receptor agonist under development for type 2 diabetes, achieved its primary efficacy end point of significant HbA1c reduction versus placebo in patients uncontrolled on metformin. Read full article.
 |
FDA announced that the Center for Drug Evaluation and Research's Office of Oncology Drug Products will now be called the Office of Hematology and Oncology Products. Read full article.
 |
Nonsteroidal anti-inflammatory drugs (NSAIDs) should be used with caution during pregnancy, as exposure may increase the risk of spontaneous abortion, reported a study published online September 6 in the Canadian Medical Association Journal. Read full article.
 |
|
An interaction between warfarin and acetaminophen may result in significant elevations of international normalized ratio, putting patients at increased risk for hemorrhagic complications, reported a literature review published in the June issue of Pharmacotherapy. Read full article.
 |
|
|
|
Contact Us |
Contact a Formulary editor Click Here
Contact a Formulary sales representative Click Here
Learn about direct mail, reprints and classifieds in Formulary Click Here |
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.
 Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|